Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,683.80up ₹2.40 (0.14%)BSE ₹1,685.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,681.40.
2 Nov: open ₹1,688.90, high ₹1,688.90, low ₹1,660.50
52-week range of traded prices to 2 Nov 2026
₹1,106.00Low, 10 Feb 2026₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,882 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.10
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.56
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,38,10850.3% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 23 of 34.
Apr 2015
8 Apr · Legal
Exchange has sought clarification from Aurobindo Pharma Limited with reference to recent news item captioned "Aurobindo pharma alleges fraud by owners of Natrol bought by the company from Plethico pharma, contracts worth $25mn. were fictitious". In this regard, The Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Mar 2015
Feb 2015
5 Feb · Dividend
Second Interim Dividend will be paid on or before February 25, 2015.5 Feb · Corporate action
Company has fixed Record Date as February 18, 2015 for the purpose of Second Interim Dividend for the year 2014-15.5 Feb · Management
Dr.C.Channa Reddy an Independent Director of the Company vide letter dated January 27, 2015 has submitted his resignation due to personal reasons. The Board of Directors of the Company at the meeting held on February 04, 2015 has noted and taken on record the resignation of Dr.C.Channa Reddy as an Independent Director of the Company.5 Feb · Dividend
Board of Directors of the Company at its meeting held on February 04, 2015 has inter-alia considered and approved second interim dividend of 200% i.e Rs.2.00 (Rupees two only) per equity share of Re.1/- each on the equity share capital of the Company for the year 2014-15. The Company in the month of September 2014 had paid first interim dividend of 150% i.e Rs.1.50 (Rupee one and paise fifty only) per equity share of Re.1/- each on the equity share capital of the Company for the year 2014-15.
Jan 2015
22 Jan · Disclosure of Voting Pattern - Clause 35A
20 Jan · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2014. Further, the Board will also consider 2nd interim Dividend, if any, for the financial year 2014-15.
Dec 2014
24 Dec · Legal
Exchange had sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "AstraZeneca sues Aurobindo over blood sugar drug patent". The Company has clarified that : Aurobindo had filed an ANDA for Saxagliptin tablets certifying P-IV against the relevant patents listed in US FDA Orange Book. Based on this, Astrazeneca had filed a case in a US District Court against Aurobindo. It is usual practice for an innovator company to file law suit against a generic company who files an ANDA with a P-IV certification for a particular product. Aurobindo is responding to the complaint appropriately within the stipulated time frame. This matter is subjudice and will not have any material impact on the Company.24 Dec · Legal
Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "AstraZeneca sues Aurobindo over blood sugar drug patent". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
25 Nov · Board meeting
Board of Directors of the Company at Meeting on November 25, 2014 has, inter alia, considered and approved raising of funds by the Company through Issue of Securities upto an amount of USD 350 Million or Rupee equivalent thereof through follow on offer, qualified institutions placement, further public offer and / or private placement or by such other method subject to approval of the shareholders. The Board has constituted a Securities Issue Committee consisting five Board Members including two Independent Directors, to do all such acts, deeds, matters and things as may be required for Issue of Securities as they may deem fit in accordance with the applicable laws.21 Nov · Board meeting
To inter alia consider raising of funds through issue of securities.18 Nov · Legal
Exchange had sought clarification from Aurobindo Pharma Limited with respect to a news item captioned "Aurobindo Pharma to spend Rs. 1,300 corore in capex". The Company has clarified that "The Company as a good corporate governance practice organizes analyst calls with management to discuss on the published quarterly results. The said news in the media has been captured from the transcript of the call pertaining to second quarter FY 14-15 earnings, held on November 07, 2014 and as published on our website. We have consistently stated that the Company s CapEx including maintenance CapEx is expected to be around Rs.600 crores for FY 2014-15, which will be spread out across APIs and Formulations. It is our broad estimation that CapEx in FY 2015-16 will be around Rs.600 to 700 crores, depending upon the cash flows and on review of CapEx needs. We consider that the news appearing in the media is incorrect and misinterpreted and does not require disclosure under clause 36 of the listing agreement, as this is nothing different than what we have been sharing in the past. We also as a policy do not comment on the media reports and market speculations".18 Nov · Legal
Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "Aurobindo Pharma to spend Rs. 1,300 corore in capex". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2014
20 Oct · Board meeting
To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2014.
Sep 2014
Aug 2014
28 Aug · Disclosure of Voting Pattern - Clause 35A
8 Aug · Disclosure of Voting Pattern - Clause 35A
5 Aug · Corporate action
Aurobindo Pharma Limited had informed the Exchange that the Company has fixed Book Closure from August 19, 2014 to August 27, 2014 (both days inclusive) for the purpose of Annual General Meeting of the company to be held on August 27, 2014. The Company has now informed the Exchange that the Company has fixed Book Closure from August 19, 2014 to August 27, 2014 for the purpose of Annual general Meeting of the Company & Interim dividend. (purpose revised)
Jul 2014
21 Jul · Board meeting
To consider, inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2014.1 Jul · Meeting